Payment of 541 shares by Williams Richard Thomas of Kinnate BiopharmaInc subject to Rule 16b-3
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
About 61% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
Kinnate |
Filed transaction by Kinnate Biopharma Inc officer. Payment of exercise price or tax liability by delivering or withholding securities
Read at macroaxis.com
Kinnate Biopharma Fundamental Analysis
We analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Kinnate Biopharma is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Kinnate Biopharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kinnate Biopharma stock to make a market-neutral strategy. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics with similar companies.
Peers
Kinnate Biopharma Related Equities
| SLRN | ACELYRIN, INC | 4.73 | ||||
| GBIO | Generation Bio | 3.74 | ||||
| PALI | Palisade Bio | 3.51 | ||||
| KRON | Kronos Bio | 2.17 | ||||
| BOLT | Bolt Biotherapeutics | 1.96 | ||||
| ERAS | Erasca | 1.95 | ||||
| PASG | Passage Bio | 1.54 | ||||
| LRMR | Larimar Therapeutics | 1.00 | ||||
| STOK | Stoke Therapeutics | 1.60 | ||||
| GLUE | Monte Rosa | 2.22 | ||||
| KROS | Keros Therapeutics | 2.32 | ||||
| KZR | Kezar Life | 2.92 | ||||
| EWTX | Edgewise Therapeutics | 3.10 | ||||
| WINT | Windtree Therapeutics | 3.13 | ||||
| DSGN | Design Therapeutics | 3.70 | ||||
| IPSC | Century Therapeutics | 3.70 | ||||
| CCCC | C4 Therapeutics | 5.25 | ||||
| SRZN | Surrozen | 5.95 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stocks Directory Find actively traded stocks across global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |